Palstrøm Nicolai Bjødstrup, Matthiesen Rune, Rasmussen Lars Melholt, Beck Hans Christian
Centre for Clinical Proteomics, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, 5000 Odense, Denmark.
Computational and Experimental Biology Group, CEDOC, Chronic Diseases Research Centre, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.
Biomedicines. 2022 Jan 12;10(1):162. doi: 10.3390/biomedicines10010162.
The human plasma proteome mirrors the physiological state of the cardiovascular system, a fact that has been used to analyze plasma biomarkers in routine analysis for the diagnosis and monitoring of cardiovascular diseases for decades. These biomarkers address, however, only a very limited subset of cardiovascular diseases, such as acute myocardial infarct or acute deep vein thrombosis, and clinical plasma biomarkers for the diagnosis and stratification cardiovascular diseases that are growing in incidence, such as heart failure and abdominal aortic aneurysm, do not exist and are urgently needed. The discovery of novel biomarkers in plasma has been hindered by the complexity of the human plasma proteome that again transforms into an extreme analytical complexity when it comes to the discovery of novel plasma biomarkers. This complexity is, however, addressed by recent achievements in technologies for analyzing the human plasma proteome, thereby facilitating the possibility for novel biomarker discoveries. The aims of this article is to provide an overview of the recent achievements in technologies for proteomic analysis of the human plasma proteome and their applications in cardiovascular medicine.
人类血浆蛋白质组反映了心血管系统的生理状态，几十年来，这一事实一直被用于在常规分析中分析血浆生物标志物，以诊断和监测心血管疾病。然而，这些生物标志物仅针对非常有限的一部分心血管疾病，如急性心肌梗死或急性深静脉血栓形成，而对于发病率不断上升的心血管疾病，如心力衰竭和腹主动脉瘤，目前尚无用于诊断和分层的临床血浆生物标志物，因此迫切需要此类标志物。血浆中新型生物标志物的发现一直受到人类血浆蛋白质组复杂性的阻碍，而在发现新型血浆生物标志物时，这种复杂性又会转化为极端的分析复杂性。不过，分析人类血浆蛋白质组的技术最近取得的进展解决了这一复杂性问题，从而增加了发现新型生物标志物的可能性。本文旨在概述人类血浆蛋白质组蛋白质组学分析技术的最新进展及其在心血管医学中的应用。
